Blau syndrome

Lore & Background

Blau syndrome classically presents in early childhood as a triad of granulomatous dermatitis, arthritis, and uveitis. Arthritis typically affects peripheral joints, mainly wrists, knees, ankles, and proximal interphalangeal joints of the hands. Tenosynovitis is another characteristic feature, with enlarged tendon sheaths, most often of the extensor tendons of the wrist, the pes anserinus, peroneal, and flexor tibialis tendon sheaths. Skin rash is typically the first symptom, usually in the first year of life, appearing as an erythematous maculo-micropapular fine scaly rash on the trunk and extremities. Uveitis presents as an insidious granulomatous iridocyclitis with posterior uveitis in 60–80% of patients.

Reader's Guide

The discovery that the gene defect in Blau syndrome involves the CARD15/NOD2 gene has sparked investigation into its function as part of the innate immune system. The innate immune system recognizes pathogen-associated molecular patterns, including bacterial polysaccharides such as muramyl dipeptide, via pattern recognition receptors like NOD2, to induce signaling pathways that activate cytokine responses. In Blau syndrome, the genetic defect seems to lead to overactivation and poor control of the inflammatory response, causing widespread granulomatous inflammation and tissue damage. The diagnosis is made by presentation of classical clinical features and can be confirmed by genetic testing and biopsy. Laboratory and imaging studies can be supportive but are usually not diagnostic. The condition was first reported in 1981 by Malleson et al. in a family with autosomal dominant synovitis, camptodactyly, and iridocyclitis, and later named Blau syndrome in 1990 by Pastores et al. The genetic defect was identified in 2001 by Miceli-Richard et al. in the nucleotide-binding domain of CARD15/NOD2, with confirmation in 2002 by Wang et al.

Did You Know?

• Blau syndrome is caused by a mutation in the NOD2 (CARD15) gene.
• Symptoms usually begin before the age of four.
• The genetic defect was found in the nucleotide-binding domain of CARD15/NOD2 in 2001.

The Immune Misfire: Innate Versus Adaptive

Periodic fever syndromes occupy a distinctive niche in immunology, operating outside the familiar framework of autoimmune disease. Rather than the adaptive immune system—where antigen-specific T cells and B cells produce autoantibodies—these conditions stem from malfunctions in the innate immune system. This distinction is critical: patients with autoinflammatory conditions do not generate the autoantibodies or targeted lymphocyte responses that define diseases like systemic lupus erythematosus. Instead, the problem lies deeper in the body's first-line defense machinery. The innate immune system, which normally responds to threats in a general, non-specific way, becomes dysregulated, triggering waves of inflammation without any external pathogen or self-antigen to justify the response. This fundamental reclassification—shifting the blame from adaptive to innate immunity—has reshaped how researchers and clinicians understand a broad family of recurrent inflammatory conditions, placing them in their own distinct category rather than lumping them with traditional autoimmune disorders.

The Clinical Landscape: Flares and Long-Term Shadows

The clinical picture of periodic fever syndromes is deceptively varied yet follows recognizable patterns. Patients typically endure cyclical episodes marked by high fever, aching joints, inflammatory skin rashes, and bouts of abdominal pain. These flare-ups can be physically exhausting and emotionally draining, particularly because they strike with a rhythm that feels predictable yet remains frustratingly imprecise in timing. Beyond the acute episodes, the longer shadow of these conditions looms large: chronic complications such as amyloidosis—a condition where misfolded proteins deposit in organs—can develop over years of repeated inflammation, threatening kidney, liver, and other organ function. The diversity within the syndrome family is notable; some conditions present with serositis lasting under three days, while others manifest with mouth ulcers, throat inflammation, and swollen lymph nodes. This breadth of presentation means a single diagnostic label rarely captures the full experience of a patient, and the overlap of symptoms across different syndromes can make identification a challenging journey, especially in children where most of these conditions first declare themselves.

The Genetic Blueprint: From Pyrin to the Inflammasome

For the majority of autoinflammatory conditions, the root cause is written into the patient's DNA from birth, with symptoms typically emerging during childhood. Familial Mediterranean fever stands as the most prevalent example, driven by mutations in the MEFV gene that encodes the protein pyrin. Under normal circumstances, pyrin is a component of the inflammasome—a molecular assembly that acts as a cellular alarm system. When the pyrin protein carries a mutation, however, it appears to trigger the inflammasome inappropriately, unleashing a cascade that culminates in the release of the pro-inflammatory cytokine IL-1β. This single molecular event sets off the fever, pain, and tissue damage patients experience. What makes this genetic insight particularly powerful is its universality: most other autoinflammatory diseases, regardless of their specific gene or protein, converge on the same endpoint—excessive IL-1β production. This shared mechanism has unified a once-scattered group of conditions under a common pathophysiological umbrella and pointed researchers toward a single, high-leverage therapeutic target.

A Therapeutic Revolution and Remaining Mysteries

The identification of IL-1β as the common thread in autoinflammatory disease has unlocked a therapeutic era that would have seemed science fiction to earlier generations of patients. Biologic agents such as anakinra, rilonacept, and canakinumab were designed to intercept or neutralize this cytokine, effectively silencing the inflammatory alarm that drives symptoms. These medications have fundamentally transformed the prognosis for many patients, shifting management from merely enduring flare-ups to actively preventing them. Yet the story is not one of complete resolution. A subset of periodic fever syndromes—including PFAPA, the most common autoinflammatory condition in children, along with adult-onset Still's disease, systemic-onset juvenile idiopathic arthritis, Schnitzler syndrome, and chronic recurrent multifocal osteomyelitis—resist a single-gene explanation. Evidence suggests these conditions are multifactorial: genetic susceptibility creates vulnerability, but an environmental trigger is needed to tip the balance into disease. This unresolved interplay between genes and environment remains one of the field's most pressing unanswered questions, and it underscores that for many patients, the full story of their illness is still being written.

Gallery